Mizuho Markets Americas LLC Lowers Stock Holdings in Haemonetics Co. (NYSE:HAE)

Mizuho Markets Americas LLC lowered its position in shares of Haemonetics Co. (NYSE:HAE) by 4.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 348,478 shares of the medical instruments supplier’s stock after selling 15,116 shares during the period. Mizuho Markets Americas LLC’s holdings in Haemonetics were worth $28,011,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of HAE. Silvercrest Asset Management Group LLC bought a new position in shares of Haemonetics in the first quarter worth $38,706,000. Price T Rowe Associates Inc. MD increased its stake in Haemonetics by 38.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier’s stock worth $48,006,000 after acquiring an additional 156,665 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Haemonetics by 311.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 25,775 shares of the medical instruments supplier’s stock valued at $2,132,000 after acquiring an additional 19,510 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Haemonetics by 26.8% during the 1st quarter. Janus Henderson Group PLC now owns 29,730 shares of the medical instruments supplier’s stock valued at $2,536,000 after acquiring an additional 6,287 shares during the last quarter. Finally, CWM LLC grew its holdings in shares of Haemonetics by 40.5% during the second quarter. CWM LLC now owns 36,526 shares of the medical instruments supplier’s stock worth $3,022,000 after purchasing an additional 10,537 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 1.7 %

NYSE HAE opened at $89.24 on Friday. The stock’s 50-day moving average price is $77.55 and its 200-day moving average price is $82.75. The company has a market capitalization of $4.48 billion, a P/E ratio of 37.03, a price-to-earnings-growth ratio of 1.43 and a beta of 0.32. Haemonetics Co. has a 52 week low of $70.25 and a 52 week high of $97.97. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. During the same quarter in the prior year, the business posted $0.99 EPS. Haemonetics’s revenue for the quarter was up 8.6% compared to the same quarter last year. On average, equities research analysts predict that Haemonetics Co. will post 4.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HAE. Bank of America assumed coverage on Haemonetics in a report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective on the stock. Citigroup lowered their price objective on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. CL King started coverage on shares of Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Finally, Barrington Research restated an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a report on Friday, November 8th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and an average target price of $107.88.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.